Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer-Reference-Cited by-同舟云学术

Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer

Published:2022-08-01 Issue:8 Volume:8 Page:1128
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Shore Neal D.¹,Renzulli Joseph²,Fleshner Neil E.³,Hollowell Courtney M. P.⁴,Vourganti Srinivas⁵,Silberstein Jonathan⁶,Siddiqui Rizwan⁷,Hairston John⁷,Elsouda Dina⁷,Russell David⁸,Cooperberg Matthew R.⁹,Tomlins Scott A.¹⁰

Affiliation:

1. Carolina Urologic Research Center, Myrtle Beach, South Carolina

2. Yale University, New Haven, Connecticut

3. Princess Margaret Cancer Centre, Toronto, Ontario, Canada

4. Cook County Health, Chicago, Illinois

5. Rush University Medical Center, Chicago, Illinois

6. Memorial Healthcare System, Hollywood, Florida

7. Astellas Pharma Inc, Northbrook, Illinois

8. Pfizer Inc, New York, New York

9. University of California, San Francisco

10. Departments of Pathology and Urology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2793567/jamaoncology_shore_2022_oi_220020_1660581536.26699.pdf

Reference12 articles.

1. Cancer statistics, 2020.;Siegel;CA Cancer J Clin,2020

2. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?;Hu;J Urol,2014

3. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.;Fleshner;Lancet,2012

4. Neoadjuvant enzalutamide prior to prostatectomy.;Montgomery;Clin Cancer Res,2017

5. Long-term efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 1- and 2-year open-label follow-up results.;Tombal;Eur Urol,2015

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials;Prostate Cancer and Prostatic Diseases;2024-04-08

2. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance;JCO Precision Oncology;2024-04

3. Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic “Advances”;Journal of Urology;2024-02

4. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer;New England Journal of Medicine;2023-10-19

5. Molecular Anatomy of Prostate Cancer and Its Implications in Active Surveillance and Early Intervention Strategies;Anatomia;2023-10-10